Nevro price target lowered to $27 from $30 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Nevro to $27 from $30 and keeps a Buy rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.